Cancer 2005; 104: 1505–1511. 3 Petruckevitch A, Del Amo J, Phillips AN et al. Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group. Int J STD AIDS 1999; 10: 38–42. 4 Frisch M, Biggar RJ, Engels EA, Goedert

JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736–1745. 5 Dal Maso L, Franceschi S, Polesel J et al. Risk of cancer in persons with AIDS in Italy, 1985–1998. Br J Cancer 2003; 89: 94–100. 6 Herida M, Mary-Krause M, Kaphan R et al. Incidence of non-AIDS-defining Selleck Doxorubicin cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21: 3447–3453. 7 International Collaboration on HIV and Cancer. Highly active antiretroviral

therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823–1830. 8 Bedimo R, Chen RY, Accortt NA et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989–2002. Clin Infect Dis 2004; 39: 1380–1384. 9 Tirelli U, Errante D, Dolcetti R et al. Hodgkin’s disease and HIV infection: clinicopathologic and virologic features of 114 patients from the Italian cooperative group on AIDS and tumors. J Clin Oncol 1995; 13: 1758–1767. 10 Re A, Casari S, Cattaneo C et al. Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2001; 92: 2739–2745. 11 Glaser click here SL, Clarke CA, Gulley ML et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998. Cancer 2003; 98: 300–309. 12 Hoffmann C, Chow

KU, Wolf E et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol 2004; 125: 455–462. 13 Errante D, Zagonel V, Vaccher E et al. Hodgkin’s disease in patients with HIV infection and in the general population: comparison of clinicopathological features and survival. Ann Oncol 1994; 5(Suppl 2): 37–40. 14 Rapezzi D, Ugolini D, Ferraris AM et al. Histological subtypes of Hodgkin’s disease in the Resveratrol setting of HIV infection. Ann Hematol 2001; 80: 340–344. 15 Rubio R. Hodgkin’s disease associated with HIV: a clinical study of 46 cases. Cancer 1994; 73: 2400–2407. 16 Gerard L, Galicier L, Boulanger E et al. Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003; 17: 81–87. 17 Montoto S, Shaw K, Okosun J et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.